Monoclonal antibodies for rheumatism in dogs, Librela

Podcast Summary: "Doctors Take the Mic - Concerns Over Arthritis Drug for Dogs" Dr. Gloria Wu discusses potential risks of Librela, an arthritis drug for dogs, highlighted in a December 21, 2024 New York Times article by Emily Anthes. Librela, a monoclonal antibody injection, has been linked to severe neurological effects, including seizures and death, despite initially listing mild side effects. Since its U.S. approval in 2023, over 3,600 adverse events have been reported, raising concerns. While many dogs benefit, others suffer severe reactions, often due to unrecognized underlying conditions. The FDA has recommended updating Librela's label. Dr. Wu advises pet owners to be informed, consult veterinarians, and consider breed-specific risks before using the drug.